Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Marco Fiorillo; Rebecca Lamb; Herbert B. B. Tanowitz; Anna Rita Rita Cappello; Ubaldo E. E. Martinez-Outschoorn; Federica Sotgia; Michael P. P. Lisanti

doi:doi:10.18632/aging.100983

← Back

Research Paper Volume 8, Issue 8 pp 1593—1606

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Figure 3. Bedaquiline greatly diminishes glycolysis in MCF7 breast cancer cells. The Seahorse XF96 analyzer was employed to determine the status of glycolysis in MCF7 cells treated with 10μM bedaquiline for 48 hours. (A) A line graph of 3 independent experiments is shown. (B, C, D, E) Note the reductions in glycolytic reserve, glycolytic reserve capacity and ECAR. (F) The plot of OCR versus ECAR shows that bedaquiline shifts MCF7 cells from an energetic to a quiescent state. * p<0.01, ** p<0.001, ns not significant.